Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer

Pelthos Therapeutics has secured the rights to marketplace non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% successful the US from Biofrontera and Ferrer Internacional.

The topical pick is indicated to dainty impetigo, a bacterial tegument corruption caused by Staphylococcus aureus oregon Streptococcus pyogenes successful some adults and paediatric patients arsenic young arsenic 2 months.

In conjunction with this acquisition, Pelthos besides completed a backstage financing circular done convertible notes, bringing successful $18m from existent investors, including Ligand Pharmaceuticals and a consortium spearheaded by Murchinson.

Terms of the latest woody necessitate Pelthos to wage $3m to Biofrontera and $1.2m to Ferrer upfront. Further payments volition beryllium connected commercialized proviso levels of the pick and aboriginal sales.

The statement besides includes royalty obligations by Pelthos connected US nett income to some Ferrer and the capitalist group.

Initially developed by Ferrer successful collaboration with Medimetriks Pharmaceuticals, Xepi received support from the Food and Drug Administration (FDA) successful 2017, becoming the archetypal caller attraction for impetigo successful much than a decade.

Although Biofrontera has held rights to the pick successful the US since 2019, determination has been small promotion of the merchandise frankincense far.

Pelthos has indicated plans for its relaunch towards the extremity of 2026.

Impetigo is seen among children and is known for its accelerated spread, peculiarly successful household households and crowded settings specified arsenic schools.

The convertible notes secured volition accrue involvement astatine 8.5% annually, with payments required each quarter.

These notes volition mature connected 6 November 2027 unless they are earlier rebought, redeemed oregon converted into mean shares of Pelthos nether circumstantial provisions.

Funds raised are besides earmarked for progressing commercialized activities for Zelsuvmi and wide operational costs.

Investors participating successful the financing volition beryllium entitled to a royalty percent connected US income of Xepi, on with milestone payments and royalties should Zelsuvmi execute support and make income successful Japan.

Legal proposal to Pelthos was provided by Sullivan & Worcester and Paul Hastings, with Piper Sandler and Lake Street Capital Markets advising connected the financing transaction.

Roth Capital Partners provided proposal connected the Xepi rights acquisition. Latham & Watkins represented Ligand, portion Kelley Drye & Warren, on with Morgan, Lewis & Bockius, acted connected behalf of Murchinson’s capitalist group.

"Pelthos acquires US rights to Xepi pick from Biofrontera and Ferrer" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.